Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

inhibikase therapeutics inc - IKT

IKT

Close Chg Chg %
1.65 0.35 21.21%

Closed Market

2.00

+0.35 (21.21%)

Volume: 2.08M

Last Updated:

Dec 26, 2025, 4:00 PM EDT

Trade Now

Company Overview: inhibikase therapeutics inc - IKT

IKT Key Data

Open

$1.79

 Day Range

1.71 - 2.05

52 Week Range

1.33 - 3.49

 Market Cap

$200.09M

Shares Outstanding

121.27M

 Public Float

99.08M

Beta

0.88

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.57

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

595.32K

  

IKT Performance

1 Week
 
 16.28%
 
1 Month
 
 31.58%
 
3 Months
 
 29.03%
 
1 Year
 
 -34.43%
 
5 Years
 
 -96.60%
 

IKT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About inhibikase therapeutics inc - IKT

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Wilmington, DE.

IKT At a Glance

Inhibikase Therapeutics, Inc.
1000 North West Street
Wilmington, Delaware 19801
Phone 1-302-295-3800 Revenue 0.00
Industry Pharmaceuticals: Major Net Income -27,519,886.00
Sector Health Technology Employees 16
Fiscal Year-end 12 / 2025
View SEC Filings

IKT Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 2.376
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 0.713
Enterprise Value to Sales N/A
Total Debt to Enterprise Value -0.005

IKT Efficiency

Revenue/Employee N/A
Income Per Employee -1,719,992.875
Receivables Turnover N/A
Total Asset Turnover N/A

IKT Liquidity

Current Ratio 26.369
Quick Ratio 26.369
Cash Ratio 26.126

IKT Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -48.662
Return on Equity -52.001
Return on Total Capital -28.975
Return on Invested Capital -51.957

IKT Capital Structure

Total Debt to Total Equity 0.116
Total Debt to Total Capital 0.116
Total Debt to Total Assets 0.112
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Inhibikase Therapeutics Inc - IKT

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- 3.10M 123.44K 260.50K
Sales Growth
+343.92% -96.02% +111.03% -100.00%
Cost of Goods Sold (COGS) incl D&A
- 6.72K 177.40K 26.27K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- 6.72K 177.40K 26.27K
Depreciation
- 6.72K 177.40K 26.27K
Amortization of Intangibles
- - - -
-
COGS Growth
- - +2,538.67% -85.19%
-
Gross Income
- 116.72K 83.10K (26.27K)
Gross Income Growth
- - -28.80% -131.61%
-
Gross Profit Margin
- - +94.55% +31.90%
-
2021 2022 2023 2024 5-year trend
SG&A Expense
17.18M 18.25M 20.17M 28.56M
Research & Development
11.36M 12.03M 13.62M 17.18M
Other SG&A
5.82M 6.21M 6.55M 11.38M
SGA Growth
+606.45% +6.21% +10.56% +41.59%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 688.78K
-
EBIT after Unusual Expense
(14.77M) (18.13M) (20.09M) (28.59M)
Non Operating Income/Expense
- 74.45K 1.06M 1.07M
Non-Operating Interest Income
- 74.45K 1.06M 1.07M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - 19.92K
-
Interest Expense Growth
- - -32.24% -100.00%
-
Gross Interest Expense
- - - 19.92K
-
Interest Capitalized
- - - -
-
Pretax Income
(14.79M) (18.05M) (19.03M) (27.52M)
Pretax Income Growth
-419.19% -22.10% -5.40% -44.62%
Pretax Margin
- -476.88% -14,625.85% -7,304.73%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(14.79M) (18.05M) (19.03M) (27.52M)
Minority Interest Expense
- - - -
-
Net Income
(14.79M) (18.05M) (19.03M) (27.52M)
Net Income Growth
-419.19% -22.10% -5.40% -44.62%
Net Margin Growth
- -476.88% -14,625.85% -7,304.73%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(14.79M) (18.05M) (19.03M) (27.52M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(14.79M) (18.05M) (19.03M) (27.52M)
EPS (Basic)
-4.8721 -4.2966 -3.5681 -1.1606
EPS (Basic) Growth
-186.58% +11.81% +16.96% +67.47%
Basic Shares Outstanding
3.03M 4.20M 5.33M 23.71M
EPS (Diluted)
-4.8721 -4.2966 -3.5681 -1.1606
EPS (Diluted) Growth
-186.58% +11.81% +16.96% +67.47%
Diluted Shares Outstanding
3.03M 4.20M 5.33M 23.71M
EBITDA
(14.08M) (18.12M) (19.91M) (28.56M)
EBITDA Growth
-712.25% -28.73% -9.88% -43.44%
EBITDA Margin
- -454.02% -14,680.73% -7,643.88%

Snapshot

Average Recommendation BUY Average Target Price 5.00
Number of Ratings 5 Current Quarters Estimate -0.128
FY Report Date 12 / 2025 Current Year's Estimate -0.53
Last Quarter’s Earnings -0.13 Median PE on CY Estimate N/A
Year Ago Earnings -1.16 Next Fiscal Year Estimate -0.598
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 3 5 5
Mean Estimate -0.13 -0.13 -0.53 -0.60
High Estimates -0.11 -0.09 -0.50 -0.38
Low Estimate -0.14 -0.17 -0.57 -1.00
Coefficient of Variance -11.76 -31.91 -5.17 -41.21

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 2 2
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Inhibikase Therapeutics Inc - IKT

Date Name Shares Transaction Value
Feb 26, 2025 Vincent E. Aurentz Director 134,427 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 Christopher H. Cabell President & Head of R&D 1,100,705 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 Mark T. Iwicki Chief Executive Officer; Director 602,346 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 David Canner Director 116,585 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Dennis N. Berman Director 39,620 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 David Canner Director 22,640 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Arvind Kush Director 116,585 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Arvind Kush Director 56,600 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Roy Freeman Director 22,640 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Mark T. Iwicki Chief Executive Officer; Director 1,794,291 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Roberto Bellini Director 116,585 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Roberto Bellini Director 73,580 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Amit Dilip Munshi Director 116,585 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Amit Dilip Munshi Director 56,600 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Dennis N. Berman Director 30,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Dennis N. Berman Director 6,667 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Dennis N. Berman Director 6,667 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Dennis N. Berman Director 3,780 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Inhibikase Therapeutics Inc in the News